In episode five of our Lessons from COVID-19 series, we capture reflections by experts and innovators on the past, present and game-changing future of the mRNA platform. Featuring Amesh Adalja, Benjamin Jones, Teresa Lambe, Daniel Perez, Stacey Schultz-Cherry, Pamela Silver, David Topham, Eric Topol and Rajeev Venkayya.
Promising mRNA vaccines years ago emerged from early-stage development, only to stall before proving themselves in clinical trials. Pushed by pandemic urgency across the notorious “Valley of Death,” this platform vastly exceeded expectations and is now poised to transform the vaccine R&D landscape. In episode 5 of our Lessons from COVID-19 series, we capture reflections by experts and innovators on the past, present and game-changing future of the mRNA platform. Exciting insights from these conversations reveal the potential of mRNA vaccines to protect against future pandemic threats including influenza, as well as to facilitate equitable access to vaccines worldwide.
Read more about seizing mRNA vaccine potential in our blog with the Global Health Technologies Coalition.
“Today we need methodologies that we can rapidly adapt so that when a new pathogen arises, we can make a vaccine against it.”